PD-L1 expression inROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening ofEGFR,ALK, andROS1-Reference-Cited by-同舟云学术

PD-L1 expression inROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening ofEGFR,ALK, andROS1

Published:2018-11-26 Issue:1 Volume:10 Page:103-110
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Lee Jongmin¹,Park Chan Kwon¹,Yoon Hyoung-Kyu¹,Sa Young Jo²,Woo In Sook³,Kim Hyo Rim⁴,Kim Sue Youn⁵,Kim Tae-Jung⁵^ORCID

Affiliation:

1. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine; College of Medicine, The Catholic University of Korea; Seoul South Korea

2. Department of Thoracic and Cardiovascular Surgery; College of Medicine, The Catholic University of Korea; Seoul South Korea

3. Division of Hematology-Oncology, Department of Internal Medicine; College of Medicine, The Catholic University of Korea; Seoul South Korea

4. Department of Radiology; College of Medicine, The Catholic University of Korea; Seoul South Korea

5. Department of Hospital Pathology; Yeouido St. Mary Hospital, College of Medicine, The Catholic University of Korea; Seoul South Korea

Funder

National Research Foundation of Korea

The Institute of Clinical Medicine Research, Yeouido St. Mary's Hospital, Catholic University of Korea

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12917/fullpdf

Reference45 articles.

1. Lung cancer: A review;Cersosimo;Am J Health Syst Pharm,2002

2. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology;Lindeman;Arch Pathol Lab Med,2018

3. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 50% expression in lung adenocarcinoma;Rangachari;J Thorac Oncol,2017

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study);Current Oncology;2024-07-30

2. Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib;Frontiers in Oncology;2024-05-21

3. Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre;ecancermedicalscience;2024-01-15

4. Lung cancer in patients who have never smoked — an emerging disease;Nature Reviews Clinical Oncology;2024-01-09

5. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective;Pathology - Research and Practice;2024-01